Evidence map›Paper›PMID 34358343›Full record

Trial reportThe British journal of dermatology2022

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

Y Zhao, L Wu, Q Lu, X Gao, X Zhu, X Yao, L Li, W Li, Y Ding, Z Song and 22 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 6 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 6 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. [Observation of the efficacy of dupilumab for treatment of atopic dermatitis in the elderly].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 4 countries.

Y ZhaoPeking University People's Hospital, Beijing, China.ORCID 0000-0002-7198-0822
L WuHangzhou First People's Hospital, Hangzhou, China.
Q LuThe Second Xiangya Hospital of Central South University, Changsha, China.
X GaoThe First Hospital of China Medical University, Shenyang, China.
X ZhuWuxi Second People's Hospital, Jiangsu, China.
X YaoHospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China.ORCID 0000-0003-3509-4775
L LiBeijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8736-6464
W LiHuashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-1186-8609
Y DingShanghai Skin Disease Hospital, Shanghai, China.
Z SongThe Southwest Hospital of AMU, Chongqing, China.
L LiuPeking University First Hospital, Beijing, China.
N DangJinan Central Hospital, Jinan, China.
C ZhangPeking University Third Hospital, Beijing, China.
X LiuUniversity of Hong Kong-Shenzhen Hospital, Shenzhen, China.
J GuChanghai Hospital of Shanghai, Shanghai, China.
J WangNingbo No.2 Hospital, Ningbo, China.
S GengThe Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0000-0001-8731-6267
Q LiuTianjin Medical University General Hospital, Tianjin, China.
Y GuoXinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
L DongResearch & Development, Sanofi, Shanghai, China.
H SuResearch & Development, Sanofi, Shanghai, China.
L BaiResearch & Development, Sanofi, Shanghai, China.
J T O'MalleyResearch & Development, Sanofi, Cambridge, MA, USA.
J LuoResearch & Development, Sanofi, Indianapolis, IL, USA.
E LawsResearch & Development, Sanofi, Bridgewater, MA, USA.
L MannentResearch & Development, Sanofi, Paris, France.
M RuddyResearch & Development, Regeneron, New York, NY, USA.
N AminResearch & Development, Regeneron, New York, NY, USA.
A BansalResearch & Development, Regeneron, New York, NY, USA.ORCID 0000-0002-7371-6486
T OtaResearch & Development, Regeneron, New York, NY, USA.
M WangMedical, Sanofi China, Shanghai, China.
J ZhangPeking University People's Hospital, Beijing, China.ORCID 0000-0002-4060-5683
Peking University · CNRegeneron (United States) · USSanofi (China) · CNSanofi (France) · FRAVEO Oncology (United States) · USCapital Medical University · CNCentral South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Hospital of China Medical University · CNFudan University · CNHangzhou First People's Hospital · CNJinan Central Hospital · CNNingbo No. 2 Hospital · CNSanofi (United States) · USSecond Affiliated Hospital of Xi'an Jiaotong University · CNSecond Military Medical University · CNShanghai Skin Disease Hospital · CNSouthwest General Health Center · USTianjin Medical University General Hospital · CNUniversity of Hong Kong - Shenzhen Hospital · CN

Funding

Regeneron PharmaceuticalsSanofi
6 · The paper itself

Abstract

backgroundDupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD).

objectivesTo evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD.

methodsIn this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both an Investigator's Global Assessment score of 0-1 and a reduction from baseline of ≥ 2 points at week 16.

resultsOverall, 165 patients (mean age 30·6 years; 71·5% male patients) were randomized; 82 patients were randomized to dupilumab and 83 patients were randomized to placebo. At week 16, 26·8% of patients in the dupilumab group and 4·8% of patients in the placebo group achieved the primary endpoint [difference 22·0%, 95% confidence interval (CI) 11·37-32·65; P < 0·001]. Compared with placebo, higher proportions of patients in the dupilumab group achieved ≥ 75% reduction in the Eczema Area and Severity Index score (57·3% vs. 14·5%; difference 42·9%, 95% CI 29·75-55·97; P < 0·001) and had ≥ 3-point (52·4% vs. 9·6%; difference 42·8%, 95% CI 30·26-55·34; P < 0·001) and ≥ 4-point (39·0% vs. 4·8%; difference 34·2%, 95% CI 22·69-45·72; P < 0·001) reductions in weekly average daily peak daily pruritus numerical rating scale scores. The incidence of treatment-emergent adverse events during the treatment period was similar in the two groups. The incidence of conjunctivitis, allergic conjunctivitis and injection site reaction was higher in the dupilumab group than in the placebo group.

conclusionsIn adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favourable safety profile.

Indexed as

Dermatitis, AtopicEczemaAdultAntibodies, Monoclonal, HumanizedChinaDouble-Blind MethodFemaleHumansMaleSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, Humanizeddupilumab

Identifiers

PMID34358343
PMCPMC9298048
OpenAlexW3189569397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.